Skip to main content

EU201

All trials

Alzheimer

EU201

Leeftijd icoon
50 - 80 years (M / F)
Diagnose icoon
Diagnosis Mild Cognitive Impairment (MCI), Light Stage Alzheimer's
Duratie onderzoek
1,5 years
Locatie icoon
Amsterdam

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently.

The research drug T-817MA is a new drug against Alzheimer’s disease. With this study, the researchers want to find out more about the safety and effectiveness of the drug.

You visit our research center every twelve weeks where you receive T-817MA tablets or placebo tablets. Half of the participants will receive the study drug and the other half the placebo. During a few visits, questionnaires will be done, blood tests and physical examinations will take place, and MRI scans and EEGs will be done. The period in which you receive the research drug is eighteen months.

This study is commissioned by Toyama.

This text has been directly translated from the Dutch trial description as approved by the Ethical Committee.

Screening – Selection

During three visits in a maximum period of six weeks, it will be determined whether you meet the study criteria and whether your health allows participation in the study. If so, you may participate in the study. The selection includes blood tests, physical examinations, memory tests, questionnaires, an MRI scan, an EEG, and a spinal tap.

Follow-up

After completing the treatment phase, participants will be followed for up to six weeks and will return to the center once for a final check-up. During this last check-up visit, questionnaires and tests will be done for your memory, among other things, a final blood test, physical examination, and a spinal tap will be performed.

A total of 14 visits were made to the research center over a period of 6 weeks (screening) and 48-96 weeks (treatment).

Who can participate?

  • You have a diagnosis of Mild Cognitive Impairment (MCI) or mild-stage Alzheimer’s disease
  • You are between 50-80 years old
  • Use of Alzheimer’s medication is permitted, provided it has been the same dose for more than three months.
  • You have a family carer who can accompany you during a few visits to the research center and answer questions about your health and functioning, among other things.

Take action against Alzheimer’s. Sign up to participate.

Latest Dementia trials

Filter

All trialsAlzheimer

Alnylam

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALN-APP is for the treatment of participants with MCI or mild dementia due to early onset Alzheimer’s disease, where the disease began before the participant was 65 years old. The study compares the effect of the new drug ALN-APP with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through an injection into the fluid surrounding the spinal cord.

audience18+

levelAlzheimer’s or mild dementia due to early onset Alzheimer’s disease

duration152 weeks

locationAmsterdam

All trialsAlzheimer

REMAD 02

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug REM0046127 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug REM0046127 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer's disease

duration9 weeks

locationAmsterdam

All trialsAlzheimer

APOLLOE4

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is taken in the form of a tablet.

audience50 - 80 years

level Early-stage Alzheimer’s disease and ApoE4/4 genotype

duration93 weeks

locationAmsterdam, Den Bosch, and Zwolle